PERBEDAAN KADAR HEMOGLOBIN SEBELUM DAN SESUDAH KEMOTERAPI PADA PASIEN KARSINOMA MAMMAE YANG DIRAWAT DI RUMAH SAKIT MOHAMMAD HOESIN
Daftar Isi:
- Backgrounds: Mammary carcinoma is a malignant tumor that occurs in breast cells. Anemia is the most common complication in mammary carcinoma patients that can be caused by chemical factors produced by mammary carcinoma or chemotherapy treatment factors. Chemotherapy can cause anemia by damaging the process of hematopoiesis which is accompanied by a decrease in hemoglobin because of the reduced amount of erythrocytes. This study aims to determine the differences in hemoglobin levels before and after chemotherapy in mammary carcinoma patients treated at Mohammad Hoesin Hospital in Palembang. Method: This study approaches using the observational analytic cross-sectional design. Sampling was done by using the consecutive sampling technique with a total of 50 respondent mammary carcinoma patients undergoing chemotherapy at RSUP Dr. Mohammad Hoesin Palembang in September 2019. Results: In this study it was found that the age group that suffered the most from mammary carcinoma was the age group 41-50 years with 51-60 years as many as 13 people (26%). The mean and standard deviation of hemoglobin levels before chemotherapy in 50 mammary carcinoma patients, 12.082 ± 1.5157, was higher than the hemoglobin levels after chemotherapy in 50 patients, 10.676 ± 1.5564. In this study, the p value is 0.000 <0.05, meaning that with a confidence level of 95% it can be stated that there are differences in hemoglobin levels before and after chemotherapy in mammary carcinoma patients. Conclusion: There are differences in hemoglobin levels before and after chemotherapy in mammary carcinoma patients.